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Abstract
Tumor-infiltrating macrophages respond to microenvironmental signals by developing a tumor-associated phenotype
characterized by high expression of mannose receptor (MR, CD206). Antibody cross-linking of CD206 triggers anergy in
dendritic cells and CD206 engagement by tumoral mucins activates an immune suppressive phenotype in tumor-associated
macrophages (TAMs). Many tumor antigens are heavily glycosylated, such as tumoral mucins, and/or attached to tumor cells
by mannose residue-containing glycolipids (GPI anchors), as for example mesothelin and the family of carcinoembryonic
antigen (CEA). However, the binding to mannose receptor of soluble tumor antigen GPI anchors via mannose residues has
not been systematically studied. To address this question, we analyzed the binding of tumor-released mesothelin to ascites-
infiltrating macrophages from ovarian cancer patients. We also modeled functional interactions between macrophages and
soluble mesothelin using an in vitro system of co-culture in transwells of healthy donor macrophages with human ovarian
cancer cell lines. We found that soluble mesothelin bound to human macrophages and that the binding depended on the
presence of GPI anchor and of mannose receptor. We next challenged the system with antibodies directed against the
mannose receptor domain 4 (CDR4-MR). We isolated three novel anti-CDR4-MR human recombinant antibodies (scFv) using
a yeast-display library of human scFv. Anti-CDR4-MR scFv #G11 could block mesothelin binding to macrophages and
prevent tumor-induced phenotype polarization of CD206
low macrophages towards TAMs. Our findings indicate that tumor-
released mesothelin is linked to GPI anchor, engages macrophage mannose receptor, and contributes to macrophage
polarization towards TAMs. We propose that compounds able to block tumor antigen GPI anchor/CD206 interactions, such
as our novel anti-CRD4-MR scFv, could prevent tumor-induced TAM polarization and have therapeutic potential against
ovarian cancer, through polarization control of tumor-infiltrating innate immune cells.
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Introduction
Macrophages show a remarkable degree of plasticity and exert
diverse functions, depending on the microenvironmental stimuli
[1]. Macrophages activated toward a classical, proinflammatory
phenotype (M1) elicit anti-tumor activity and promote TH1
immune responses [2], while macrophages with an alternative
phenotype (M2) promote TH2 immune responses and tissue
remodelling. Tumor polarization of macrophages represents an
essential immune escape mechanism that results in a hampered
innate immune response leading to a poor adaptive immunity
[3,4]. Recent studies suggest that tumor-induced differentiation of
macrophages is a continuous process with several intermediate
phenotypic states [5,6], possibly reversible [7]. Tumor-associated
macrophages (TAMs) share properties with M2 macrophages,
including high expression of IL10 and mannose receptor (CD206),
and low expression of IL-12 [8]. TAMs constitute a predominant
cell population of the tumor microenvironment and are correlated
with poor clinical outcome [9]. However, the identification of
factors responsible for TAM polarization is not complete. Mouse
studies suggest a critical role for CSF-1 in attracting monocytes at
the tumor site [1], while cytokine imbalance in favour of IL-10 and
TGF-b in the microenvironment could foster immunosuppression
and polarize macrophages to elicit pro-tumoral functions [10].
Hagemann and colleagues have also proposed that macrophage
differentiation towards TAMs involves a ‘‘chemical conversation’’
via exchange of soluble extracellular mediators between ovarian
tumor cells and macrophages [11,12].
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[13,14]. CD206 is a highly conserved calcium-dependent multi-
lectin and a pattern recognition receptor (PRR) that mediates non-
opsonic phagocytic uptake of a wide variety of microbes and that
also functions as an endocytic receptor for glycans [15,16,17,18].
CD206 comprises of two distinct extracellular lectin binding sites,
one that recognizes sulfated sugars [19,20] and another that
preferentially binds to branched sugars with terminal mannose,
fucose or N-acetyl-glycosamine [21,22,23,24]. Although the role of
CD206 in innate immunity is well described [25,26], its
contribution to tumor immunity remains understudied. Recent
evidence demonstrated that CD206 promotes the circulation of
lymphocytes and tumor cells through the lymphatics and to the
draining lymph nodes [27]. In addition, CD206 cross-linking with
an anti-MR mAb (clone PAM-1) can drive DCs differentiation
into APCs promoting T-cell anergy [28], which contributes to the
failure of the immune surveillance against solid tumors and
facilitates tumor growth and spreading [29,30,31].
Ovarian cancer releases various glycoproteins and many of
these tumor antigens have been evaluated as biomarkers [32].
Well-studied tumor antigens such as mesothelin [33], CEA
[34,35], and folate receptor [36,37] are displayed to the cell
surface through a GPI-anchor. GPI anchor proteins are
structurally and functionally diverse and play vital roles in
numerous biological processes [38,39], including cell adhesion,
localization on a specific membrane, association with other
membrane proteins and cell signaling [40]. GPI-anchors are
evolutionary conserved and their presence on parasite surface
proteins activates PI3K pro-inflammatory pathway upon interac-
tion with host macrophages [41]. GPI-anchored glycoproteins are
associated to lipid raft domains [42,43] that are characterized by a
liquid ordered arrangement of lipids depending on highly
saturated sphingomyelin species (SM) tightly associated with
cholesterol (CHOL). CHOL/SM ratio is typically close to 1 in
lipid raft [44,45], and a high SM/Phosphatidylcholine (PC) ratio
thought to maintain low polyunsaturated glycerophospholipids is
also characteristic of lipid rafts, as compared with more fluid
fractions of the membrane [46]. GPI anchors are released from
cell membranes by two main mechanisms, shedding of intact GPI
anchors in complexes with membrane lipids or in membrane
vesicles (exosomes) [47], and proteolytic cleavage mediated by the
bacterial GPI-phospholipase C (GPI-PLC), the mammalian GPI-
phospholipase D (GPI-PLD) [48], or by the angiotensin-convert-
ing enzyme (ACE) that frees terminal mannose [49].
Mesothelin is a GPI-anchored cancer biomarker over-expressed
by lung cancers, mesotheliomas, pancreatic and ovarian adeno-
carcinomas [33]. It is also a soluble biomarker detectable in body
fluids of patients with epithelial cancers [36,50,51,52,53,54].
Mesothelin binds with high affinity to CA125 through glycan
interaction and mediates heterotypic cell adhesion that may be
involved in ovarian carcinoma pathogenesis and micrometastatic
disease [55,56,57]. However, despite some progress [58,59,60], the
role of mesothelin during cancer development remains to be fully
understood.
We hypothesized that that MR engagement by tumor-released
mesothelin contributes to macrophage polarization. We further
hypothesized that tumor-released mesothelin binds to mannose
receptor expressed by macrophages via GPI anchor-mannose
residues. To address these questions, we used soluble mesothelin
from patient samples, tumor cell lines and cells transfected with a
GPI-truncated form of mesothelin. Binding experiments were
performed in medium and in the presence of blocking reagents
such as mannan, a high affinity ligand for mannose receptor
[28,61,62], or of novel recombinant antibodies of human origin
(scFv) directed against the mannose receptor domain 4 (CDR4-
MR). Alterations of macrophage polarization were monitored by
qRT-PCR, flow cytometry, and bead-based arrays. The demon-
stration of the attachment of a GPI anchor to soluble mesothelin
was performed by ELISA assays, tandem mass spectrometry and
co-immunoprecipitation.
Results
Tumor-released mesothelin binds to ascites-infiltrating
macrophages from ovarian cancer patients
To explore whether tumor-released mesothelin could bind to
macrophages, frozen cells isolated from human ascites (n=6) or
from solid tumors (n=8) of ovarian cancer patients, as well as
healthy donor monocytes (n=12), were stained with anti-Epcam,
anti-CD45, anti-CD14, anti-CD206, anti-mesothelin (K1) mAbs
and 7-AAD. Viable Epcam
2CD45
+CD14
+ cells were gated and
analyzed for CD206 expression and binding to soluble mesothelin.
Figure 1 shows that the majority of CD45
+CD14
+ cells from
ascites samples expressed high level of CD206 and soluble
mesothelin bound to about a fifth of them (Fig. 1A upper
panels and Fig. 1B). Lower levels of CD206 were expressed by
CD45
+CD14
+ cells from solid tumor samples and mesothelin
bound only to a low percentage of them (Fig. 1A middle panels
and Fig. 1B). Finally, none of the healthy donor CD45
+CD14
+
cells expressed CD206 or bound to anti-mesothelin K1 antibody
(Fig. 1A lower panels and Fig. 1B). These results were the first
evidence that soluble mesothelin could bind to ascites-infiltrating
CD206
high macrophages from ovarian cancer patients and to some
tumor-infiltrating CD206
low macrophages.
Tumor-released mesothelin binds to CD206
high
monocytes from normal donors
To model the binding of mesothelin to macrophages, we set up
two types of in vitro assay systems using healthy donor monocytes
and in vitro differentiated CD206
low/high macrophages that were 1/
briefly incubated with conditioned media or with ascites fluids, or
2/ co-cultured for 3 days in transwells with OVCAR5 ovarian
cancer cell line or with 293 MESOIg secreting GPI-truncated
mesothelin [63] and, as controls, with wild type 293 cell line.
CD206
low and CD206
high macrophage phenotypes are illustrated
in Fig. S1. After 30 min incubation, mesothelin from ascites fluids
bound to CD206
high macrophages (Fig. 2A,) but mesothelin from
cell line conditioned media did not (Fig. 2A). Monocytes were not
bound by soluble mesothelin in any of these conditions (Fig. 2B).
However, after 3 days of transwell co-culture, OVCAR5-released
mesothelin bound to monocytes (Fig. 2C,) but 293 MESOIg-
released mesothelin did not (Fig. 2C). These results show that
mesothelin binding to healthy donor monocytes was proportional
to CD206 expression, which supported the hypothesis that soluble
mesothelin bound to CD206. In addition, the lack of binding of
GPI-truncated mesothelin to monocytes suggested that GPI
anchor contributed, at least in part, to mesothelin binding to
CD206.
Tumor-released mesothelin binds to CD206
To further assess whether mesothelin binding was mediated
through mannose receptor, we co-cultured CD206
high macro-
phages and OVCAR3 tumor cells in medium or in the presence of
mannan, a high affinity ligand for mannose. Figure 3A shows that
the presence of 1 mg/ml of mannan during the co-culture
completely abrogated the binding of tumor-cell released mesothe-
lin to CD206
high macrophages.
Mesothelin GPI Anchor Binding to Mannose Receptor
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28386To confirm that mesothelin binding occurred specifically
through mannose receptor, rather than through other lectins also
bound by mannan [64], we sought to isolate recombinant
antibodies (scFv) specific for the mannose binding domain of
mannose receptor (CRD4-MR) [65]. To do so, we isolated anti-
CRD4-MR scFvs from a novel yeast-display human scFv library
[66], using a combination of magnetic and flow sorting
[63,66,67,68] and a yeast-secreted recombinant CRD4-MR
protein (rCRD4-MR).
Three anti-CRD4-MR scFvs (G11, B2 and H11) were isolated
and sequenced (Table S1). The scFv analysis was performed
using the Kabat system from the NCBI Ig blast website (http://
www.ncbi.nlm.nih.gov/igblast/). B2 and G11 CDR3s on the
nucleotide level look almost the same except for somatic mutation,
which implies that they both came from the same B-cell clone.
Anti-CRD4-MR scFvs were validated for binding to rCRD4-MR
by ELISA (Fig. S2A), and to CD206
low and CD206
high
macrophages by flow cytometry (Fig. S2B). While anti-CRD4-
MR #G11 and #B2 scFvs exhibited the highest binding to
rCRD4-MR (Fig. S2A), all three anti-CRD4-MR scFvs bound
equally well to CD206
high macrophages. Anti-CRD4-MR scFv
binding intensity was proportional to the levels of CD206
expressed by the macrophages and none of the anti-CRD4-MR
scFvs bound to CD206
- monocytes (Fig. S2B). Finally, the pre-
incubation of macrophages with rCRD4-MR protein blocked anti-
CRD4-MR #G11 and #B2 scFv binding, further confirming the
specificity of these scFvs for CD206 (data not shown).
We next tested the ability of anti-CRD4-MR scFvs to block
mesothelin binding to macrophages during co-culture with tumor
cells. Figure 3B shows that anti-CRD4-MR scFv #B2 could
completely block tumor-cell released mesothelin binding to
CD206
high macrophages, while the blocking activities of anti-
CRD4-MR scFvs #G11 and #H11 were intermediate or low,
respectively (Fig. 3C,D). Anti-CRD4-MR scFv #G11 and #B2
could also block mesothelin binding to CD206
low macrophages co-
cultured with tumor cells (Fig. 4B–D). These results further
supported that tumor-released mesothelin binding to monocytes
and macrophages was mediated by CD206.
Anti-CDR4-MR scFv #G11 prevents tumor-induced
polarization of CD206
low macrophages
Hagemann and colleagues demonstrated that ovarian tumor
cells cause dynamic changes in the macrophage secretion profile of
cytokines, chemokines and matrix metalloproteases [11]. We
confirmed that our transwell co-culture settings could also induce
tumor-induced polarization of monocytes and macrophages with
upregulation of CD206 (Fig. S3A) and characteristic changes of
cytokine profiles (Fig. S3B,C). To assess whether CD206
engagement could alter macrophage polarization, CD206
low and
CD206
high macrophages were co-cultured with tumor cells in
medium or in the presence of 1 mg/ml mannan or of 5 mg/ml of
anti-CRD4-MR scFvs#B2, #H11, or #G11. After 3 days of co-
culture, CD68+ macrophages were isolated and the expression of
CD206 and scavenger receptor (SR-A) was analyzed by flow
cytometry. Addition of anti-CRD4-MR scFv #G11 (Fig. 5A,
condition 6) and, to a lower extend, of scFv #B2 (Fig. 5A,
condition 5), could inhibit the upregulation of CD206 and SR-A
in CD206
low macrophages co-cultured with tumor cells. The
addition of mannan (Fig. 5A, condition 4) or of anti-CRD4-MR
scFvs #H11 (Fig. 5A, condition 7) did not. We further analyzed
the effects of anti-CRD4-MR scFvs #G11 on macrophage
expression profiles for IL-10, TGF-b, IL-12, IL-6 and TNF-a at
Figure 1. Mesothelin binding to CD14
+ ascites-infiltrating cells from ovarian cancer patients. A. Total cells from ascites (upper panels) or
solid tumors (middle panels) from ovarian cancer patients gated on CD14
+ CD45
+ (left panels) after exclusion of cells stained with EpCam and 7-AAD.
Gated cells were labeled with APC anti-CD206 and PE anti-mesothelin K1, as indicated. CD14
+ CD45
+ cells freshly purified from peripheral blood of
healthy donors (lower panels) and isotypes IgG1 (APC and PE) were used as negative controls. B. Percentages of CD45
+CD14
+CD206
+ cells in solid
tumors (grey bars, n=8), ascites samples (black bars, n=6), and healthy donors (white bars, n=12) that bind (CD206
+ K1
+) or not (CD206
+ K1
-)t o
mesothelin. Statistical significance was determined by unpaired t-test analysis (***, P=0.001). Error bars represent standard error of mean (SEM).
doi:10.1371/journal.pone.0028386.g001
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CRD4 MR scFv #G11 preserved CD206
low macrophage
phenotype during co-culture with tumor cells, as shown by the
up-regulation of IL-12 (Fig. 5D,I, condition 4), TNF-a
(Fig. 5E,J, conditions 4,6), and IL-6 (Fig. 5F,K, conditions
4,6). Consistent with these findings, IL-10 and TGF-b mRNA
transcript levels (Fig. 5B,C conditions 4,6) were downregulated
by the treatment with anti-CRD4-MR scFv #G11, as well as the
TGF-b protein levels (Fig. 5H, conditions 4,6). Of note, IL-10
protein levels did not correlate with mRNA levels within the
timeframe of our analysis (Fig. 5G). Anti-CRD4 MR scFv #G11
could also partially revert the CD206
high phenotype to that of a
CD206
low for TGF-b and IL-6 production (Fig. 6A–D,
conditions 4,6), but did not significantly affect the other
analyzed cytokines (Fig. S4). These results suggest that anti-
CRD4 MR scFv #G11 can control tumor-induced polarization of
macrophages. Finally, because the effects of anti-CRD4 MR scFv
#G11 on macrophage phenotype were more pronounced in the
absence of tumor cells (Fig. 5B–K, condition 2), CD206
engagement by soluble mesothelin may compete with anti-CRD4-
MR scFv binding.
GPI anchor remains attached to soluble mesothelin after
release by tumor cells
Cell surface attachment of mesothelin depends on a glycopho-
sphatidylinositol (GPI) anchor but, to our knowledge, the release
mechanism of mesothelin from tumor cells has not been described.
It was thus unclear whether soluble mesothelin remains linked to
the GPI anchor in patient fluids or in tumor-conditioned media.
To answer this question, we exploited two biochemical charac-
teristics of GPI anchors that are 1/ GPI core specific composition
in glycan moieties [69], and 2/ GPI anchor insertion in lipid raft
microdomains [70,71]. To address whether GPI anchors were
attached to soluble mesothelin, we developed an ELISA double
determinant assay using an anti-mesothelin antibody as capture
reagent and Endotoxin alpha (Endo-A) as detection reagent; endo-
A specifically binds to GPI core glycan moieties [72,73,74]. The
assay is referred to as ‘‘Endo-A meso ELISA’’ in the rest of the
study. We then compared the results of the Endo-A meso ELISA
with these of a classical anti-mesothelin ELISA assay. Figure 7
shows that, as expected, the anti-mesothelin ELISA assay detected
soluble mesothelin in all ascites fluids as well as in conditioned
media from ovarian cancer cell lines and from 293 MESOIg
Figure 2. Mesothelin binding to healthy donor monocytes and macrophages co-cultured with tumor cells. A–B. Short term
incubations. In vitro differentiated CD206
+ macrophages (A) and CD206
2 monocytes (B) from healthy donors were incubated with conditioned
media from OVCAR3, OVCAR5, 293 MESOIg, or ascites fluids from patients #1714 and #1647 after blocking with 10 mg/ml of human IgG. As negative
controls, cells were incubated with conditioned media from 293WT cell line, RPMI+10% FBS medium. Isotype control IgG1 antibodies (APC and PE) on
cells incubated with RPMI/FBS. C. Transwell co-cultures: Freshly isolated monocytes were cocultured with OVCAR5 or 293mesoIg. As negative
controls, monocytes were incubated with 293WT or with RPMI+10% FBS medium only. Grey areas, PE isotype IgG1 control; open area, PE-
conjugated anti-mesothelin mAb (K1). Results representative of 3 or more independent experiments.
doi:10.1371/journal.pone.0028386.g002
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mesothelin fused to an Ig domain [57]) (Fig. 7A). Endo-A meso
ELISA also detected soluble mesothelin in ascites fluids and
conditioned media from cancer cell lines. However, Endo-A meso
ELISA could not detect soluble mesothelin released by 293
MESOIg cell line that is truncated for the GPI anchor (Fig. 7B).
Figure 3. Blocking of mesothelin binding to CD206
high macrophages with mannan or anti-CRD4 MR scFvs. Macrophages were labeled
with PE anti-mesothelin antibody K1 (lines) or with PE isotype control Ab (grey area) after in vitro differentiation with IL4/IL10 and 72 hr co-culture
with OVCAR3 cells (bold lines). Blocking conditions (dashed lines) included (A) mannan, or (B–D) anti-CRD4 MR scFvs #B2 (B), #G11 (C)o r#H11
(D). As control, CD206
high macrophages were incubated in medium only (dotted lines). Results representative of 3 or more independent
experiments.
doi:10.1371/journal.pone.0028386.g003
Figure 4. Blocking of mesothelin binding to CD206
low macrophages with anti-CRD4 MR scFvs. Macrophages were double stained with PE
anti-CD206 mAb and APC anti-mesothelin antibody (K1) after in vitro differentiation with IFN-c/LPS and 72 hr co-culture with OVCAR3 cells (B).
Blocking conditions included anti-CRD4 MR scFvs #G11 (C) and #B2 (D). As negative control, CD206
low macrophages were labeled with isotype
control antibodies (A). Results representative of 3 or more independent experiments.
doi:10.1371/journal.pone.0028386.g004
Mesothelin GPI Anchor Binding to Mannose Receptor
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carries a GPI-anchor after tumor-release in ascites fluids and in
tumor-conditioned media.
We next addressed whether mesothelin was inserted into lipid
rafts. Mesothelin could be detected by an anti-mesothelin antibody
(K1) in the lipid raft fractions extracted from OVCAR3
membranes and separated by electrophoresis, consistent with the
fact that GPI-anchored proteins are associated with lipid raft
domains (data not shown) [42,43]. We then used tandem mass
spectrometry to analyze the composition of lipids associated with
soluble mesothelin. Figure 8A shows that soluble mesothelin
immunoprecipitated from OVCAR3 conditioned medium is
associated with lipids exhibiting a CHOL/SM ratio of 1 and a
remarkably high SM/PC ratio (8.1). The most abundant
molecular species of SM is comprised of the saturated palmityl-
SM (m/z 703). These ratios of CHOL and saturated SM were
consistent with lipid raft composition. These results support the
fact that tumor-released mesothelin remains associated lipid
remnants of rafts.
Lastly, we investigated whether mesothelin resides in tumor-
released exosomes, We immunoprecipitated mesothelin from
tumor cell supernatants and looked by western blot for the
presence of co-immunoprecipitated exosomal proteins TSG101
and ALIX [75]. Tumor cell lysate (Fig. 8B, left lane) was used as
a positive control. TSG101 and ALIX exosomal proteins were
detected only in OVCAR3 cell lysate (Fig. 8B, right lane). We
conclude that the absence of co-immunoprecipitation of exosomal
proteins with tumor-released mesothelin demonstrates that
mesothelin does not reside in tumor-released exosomes.
Discussion
Polarized inflammation is a hallmark of several pathologic
conditions including infection and cancer, and plays a central role
in disease progression and/or resolution. Tumor associated
macrophages (TAMs) are critical for cancer growth and
development, but the signals eliciting TAM phenotype remain
incompletely understood. We provide here the first evidence that
the soluble cancer biomarker mesothelin binds to macrophages.
To analyze the functional consequences of the binding, we isolated
human recombinant antibodies directed against the domain 4 of
the mannose receptor (anti-CRD4-MR scFv). Anti-CRD4-MR
scFv #G11 could block the binding of tumor-released mesothelin
to mannose receptor and prevent in vitro tumor-induced TAM
Figure 5. Effects of anti-CRD4 MR scFvs on the cytokine production of CD206
low macrophages during co-culture with tumor cells.
A. Flow cytometry analysis of CD206 (black bars) and SR-A (white bars) expression of CD206
low macrophages after 72 hr-incubation in medium (2),
or co-culture with OVCAR3 cells in medium (3), or in the presence of mannan (4), anti-CRD4 MR scFv #B2 (5), #G11 (6), or #H11 (7). As negative
controls, macrophages were labeled with isotype control antibodies (1). B–I. CD206
low macrophages were incubated in medium (1–2), or co-cultured
with OVCAR3 (3–4) or OVCAR5 (5–6) cells during 72 hrs. Five mg/ml of anti-CRD4 MR scFv #G11 were added in conditions 2, 4 and 6. Real-time PCR
(B–F) and cytokine bead array analysis (G–K) were performed to measure (B,G) IL10; (C,H) TGF-b;( D,I) IL-12; (E,J) TNF-a and (F,K) IL-6. Results
representative of 2 or more independent experiments.
doi:10.1371/journal.pone.0028386.g005
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tumor-released mesothelin with mannose receptor expressed by
macrophages was mediated, at least in part, by mesothelin GPI
anchor. The attachment of tumor-released mesothelin to a GPI
anchor was shown using a novel ELISA assay that detects soluble
molecules bearing both a mesothelin epitope and GPI core glycan
moieties, as well as by lipid profiling of mesothelin immunopre-
cipitated from tumor cell conditioned media. No co-immunopre-
cipitation of exosomal proteins with mesothelin was observed,
excluding the possibility that other surface proteins released in
exosomes could mediate mesothelin interaction with mannose
receptor. These results support the hypothesis that tumor-released
mesothelin GPI anchor contributes to TAM polarization through
the engagement of mannose receptor.
Tumor overexpression of glycoproteins such as mesothelin has
mainly been used as a mean of biomarker identification
[76,77,78,79,80,81], but the study of their functional roles during
cancer development remains preliminary [82,83]. Patankar and
colleagues discovered that CA125, the most studied biomarker for
ovarian cancer, binds to NK cells via siglec-9, and that the binding
suppresses NK function [84,85,86]. Allavena and colleagues
recently described the active role of mucin proteins such as
TAG-72 and CA125 in promoting an immune suppressive
phenotype of human TAMs [87]. Our results suggest that
mesothelin GPI anchor contributes to macrophage phenotype
polarization. Altogether, these findings highlight the ability of
tumor antigens to suppress tumor rejection through the manip-
ulation of innate immunity.
Pattern recognition receptors (PRR) are central to innate
immunity and include toll-like receptors (TLRs) and mannose
receptor (CD206/MR). MR binding by exogenous and endoge-
nous factors has been reported to elicit diverse cell stimulation and
differentiation programmes in a ligand-dependent manner. For
example pathogen binding to MR triggers NF-kB activation [88]
or PPARgamma activation [89,90]. In addition, recent studies
indicate that MR complements TLR signalling in proinflamma-
tory responses [91] and specifically synergizes with TLR2 in
activating a NF-kB-dependent proinflammatory responses [92].
TLR2 recognizes lipoproteins and peptidoglycans [93] from
exogenous origins such as protozoa GPI anchors [94], as well as
from endogenous origin such as versican, an extracellular matrix
proteoglycan upregulated in many human tumors and a potent
inducer of macrophage activation [95]. The ability of cancer cells
to subvert components of the host innate immune system and
promote an inflammatory microenvironment favorable for cancer
growth, including soluble factors that bind to myeloid cells
[95,96,97], makes it conceivable that mannose receptor engage-
ment by GPI anchors linked to tumor antigens such as mesothelin,
folate receptor, CEA, and CaMOV18 [98], may represent another
cancer strategy to escape immune surveillance [99]. A better
understanding of the molecular mechanisms underlying PRR
engagement by tumor antigens may lead to substantial new
insights with important implications for the development of novel
therapeutics for cancer treatment. We conclude that anti-CRD4-
MR scFv #G11 can prevent tumor-induced macrophage dynamic
changes, which provides a proof of principle for the targeting
Figure 6. Effects of anti-CRD4 MR scFvs on CD206
high macrophage phenotype during co-culture with ovarian cancer cell lines.
CD206
high macrophages were incubated in medium (1–2), or co-cultured with OVCAR3 (3–4) or OVCAR5 (5–6) cells during 72 hrs. Five mg/ml of anti-
CRD4 MR scFv #G11 were added in conditions 2, 4 and 6. Real-time PCR (B–C) and cytokine bead array analysis (D–E) were performed to measure
(A,C) TGF-b; and (B,D) IL-6. Results representative of 2 or more independent experiments.
doi:10.1371/journal.pone.0028386.g006
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innate immune response towards tumor rejection. We propose
that interfering with tumor antigen binding to MR could prevent
TAM polarization and have therapeutic potential against solid
tumors.
Materials and Methods
Human samples
Healthy Monocytes were obtained from the Human Immunol-
ogy Core of the University of Pennsylvania. Ascites and solid
tumors samples from ovarian cancer patients were obtained from
the Ovarian Cancer Research Center’s patient sample repository
of the University of Pennsylvania.
Antibodies
Anti-mesothelin ELISA kit (catalog # DY3265) was purchased
from R&D Systems. Anti-human CD206-PE, CD206-APC,
CD163-PE mouse monoclonal antibodies (mAb) and 7-AAD were
obtained from BD. Anti-human, anti-mouse CD68-FITC and anti-
V5 mAb-AF647 were from Serotec. Anti-human Mesothelin (K1),
K1-PE, anti c-myc mAb and anti-mouse HRP labeled antibody
werepurchasedfrom Santa Cruz. APC, PE-labeled orHRP-labeled
streptavidin (SA-APC, SA-PE and SA-HRP, respectively), anti-
human IL-10-PE, IL-12-PE, CD14-FITC, CD14-PE-CY7, CD45-
APC-CY5 mAbs, and rat anti-mouse IL-10-APC, IL-12-PE,
CD11b-PerCpCy5, CD45-APC-Cy7, Brefeldin A were purchased
from eBiosciences. SA-polyHRP was purchased from Fitzerald
(PolyHRP80 Streptavidin, catalog #65R-S105PHRP). The isotype
controls mIgG-PE, rIgG-PE, rIgG-APC, rIgG-PerCpCy5, rIgG-
APC-Cy7, and rIgG-PE-Cy7 were from eBiosciences and anti-
mouse-AF488 from Invitrogen. Goat anti-human mesothelin was
purchased from R&D Systems (cat# AF3265). Mouse anti-human
Alix was purchased from AbD Serotec. Rabbit anti-human
TSG101 and goat anti-rabbit HRP were from Abcam. Anti-human
B-actin conjugated to HRP was obtained from Sigma.
Cell culture
Cell lines. Ovarian cancer cell lines Ovcar3, Ovcar5, A1847
and C30, as well as wild type (WT) 293, were acquired from
Figure 7. Detection of mesothelin in ovarian cancer ascites and conditioned media. ELISA assays of ascites fluids from ovarian cancer
patients (#1714; #1686; #1647; #1753; #1756; #1773) and conditioning media derived either from ovarian cancer cell lines (A1847; OVCAR3;
OVCAR5) or from 293 cell lines, wild type (293WT) or transfected to secrete a GPI anchor-truncated mesothelin fused to Ig (293 MESOIg). (A) Anti-
mesothelin ELISA double determinant assay using anti-mesothelin mAbs as capture and detection antibodies (R&D Systems). Results representative
of two independent experiments. (B) ELISA double determinant assay using anti-mesothelin mAb (K1) as capture antibody and biotinylated
Endotoxin Alpha as detection reagent, followed by HRP-labeled streptavidin. Colorimetric signal was developed with TMB substrate solution,
quenched with sulfuric acid and read at 450 nm on a Biotek ELISA reader.
doi:10.1371/journal.pone.0028386.g007
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[63].
In vitro maturation of monocytes. The procedure of
macrophages differentiation was adapted from Porcheray et al
[7]. Briefly, freshly purified monocytes from healthy donors
(Human Immunology Core of the University of Pennsylvania)
were cultured at a density of 1610
6 /ml in the presence of 10 ng/
ml of M-CSF and 1 ng/ml of GM-CSF for 8 days. Media with
growth factors was refreshed at day 3 and at day 6. Further
polarization was induced with 10 ng/ml of IFN-c and LPS for 4
days to obtained CD206
low macrophages or with 10 ng/ml IL4
and IL-10 to obtain CD206
high macrophages (Fig. S1). In some
experiments, monocytes were incubated 3 days in the presence of
M-CSF and GM-CSF and incubated with tumor cells in transwells
to upregulate CD206 expression.
Transwell co-culture. Ovarian cancer cell lines OVCAR3
and OVCAR5, 293 MESOIg or WT 293 cell lines were collected
using versene and plated at 0.5610
6 on the bottom part of 6-well
transwell plates. Freshly isolated monocytes or in vitro maturated
macrophages were collected by gentle scrapping and plated at
1610
6 in the transwell inserts. Cells were at first co-cultured in
RPMI supplemented with 10% FBS at 37uC in presence of 5%
C02. CD206
null monocytes and CD206
low macrophages co-
cultured for 3 days with OVCAR3 cells consistently upregulated
CD206 expression and developed an alternative phenotype (Fig.
S3). For blocking assays, mannan (1 mg/ml, Sigma) or scFvs
(5 mg/ml) were added to culture medium at day 1 and renewed at
day 2. In other experiments, blocking of the non-specific binding
of mouse monoclonal antibodies to macrophage Fc receptors was
obtained using serial dilutions of human IgG protein at
concentrations of 0.01 mg/ml, 0.1 mg/ml or 1 mg/ml, added at
day 0 and day 2 to. At day 3, macrophages were collected from the
transwell inserts by pipetting and directly used for flow cytometry
staining or RNA extraction.
Isolation of anti-CRD4-MR recombinant antibodies (scFv)
Mannoses specifically bind to the domain 4 of mannose receptor
(CRD4-MR) (gi#145312260) [100]. To isolate scFv capable to
block mannose binding to the mannose receptor, we first cloned
Figure 8. Lipid analysis of mesothelin. (A) Tandem mass spectrometry (ESI_MS2) of choline-containing phospholipids, phosphatidylcholine (PC)
and sphingomyelin (SM). Lipids were extracted by the chloroform/methanol solvent Folch mixture from their association with the
immunoprecipitated mesothelin from OVCAR3 cell culture supernatant. The high proportion of SM relatively to PC in the supernatant is revealed
by the amplitude of peak m/z 703 (palmityl-SM) compared with peaks at m/z 732 (32:1 PC), 760 (34:1 PC) and 786 (36:2 PC). Parent phospholipids of
the phosphorylcholine ion (+184) are indicated as (total carbon number in acyl chains:double-bond number PC). Cholesterol assay by MS2 is obtained
after acetylation of the non esterified sterol by recording of the transition 446 (acetyl-cholesterol + NH+4) to 369 (not shown). SM/cholesterol molar
ratios are given as mole/mole after calibration. (B) Western Blot analysis of immunoprecipitated mesothelin from tumor conditioned media (right
lane) and tumor cell lysates (left lane) as positive control. Membranes were probed with anti-Mesothelin, -TSG101, - Alix, or -b actin, as indicated.
Signals were detected by ECL.
doi:10.1371/journal.pone.0028386.g008
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+ cells isolated from
an ovarian cancer patient ascites. First strand cDNA was
synthesized using 1 mg of RNA from ascites CD14
+ cells by
reverse transcription PCR using oligo-dT primers. cDNA
encoding CRD4-MR was amplified by PCR using the forward
primer 59-ggtggaggttctggtggtggtggatctgatgttttgaaatgtgatgaaaaggc-
39, and the reverse primer 39-ctactatgtcttggaatgatattaatgtcgacgg-
taagcctatccctaaccctctcctcggtc-95) that enabled the addition of
recombination sequences for cloning by gap repair in p416 BCCP
vector for yeast-secretion [66]. CDR4-MR cDNA PCR fragment
was then purified by gel extraction (Qiagen gel extraction kit),
verified by sequencing for identity with the published sequence
and inserted by gap repair in p416 BCCP vector. Yeast secreted
CRD4-MR recombinant protein was validated by western blot
using anti-V5-HRP mAb. The isolation of anti-CRD4-MR scFv
from a yeast-display scFv library was performed as described in
[66] with the following modifications. The yeast-display scFv
library was first enriched by two rounds of magnetic sorting using
45.5 pmol of CRD4-MR recombinant protein (rprot) biotinylated
with EZ-link Sulfo-NHS-LC-Biotin kit (Pierce). Screenings were
then performed by three rounds of flow sortings using BD
FACSAria
TM cell sorter and 22.72 pmol to 2.27 pmol of CRD4-
MR rprot. CRD4-MR-specific yeast-display sub-library was
shuffled into p416 BCCP yeast-secreting vector.
The first validation of scFv binding to CRD4-MR was
performed by capture ELISA as described in [68]. Amino plates
with coated with serial dilutions of His-purified scFv diluted from
10 to 0.001 mg/ml in carbonate-bicarbonate buffer (Sigma).
Biotinylated CRD4-MR was added at 0.2 mg/ml and detected
by SA-HRP and TMB (KPL). ELISA plates were read as
described for ELISA double determinant assays. Anti-CRD4
scFvs were then tested by flow cytometry for their binding to
CD206
low and CD206
high macrophages. Anti-CRD4-MR scFvs
(5-10 mg/ml) were first preincubated with AF647-labeled anti-V5
mAb (1 to 2.5 mg/ml). Anti-V5/CRD4-MR scFvs were then
incubated with macrophages for 30 min at 4uC in FACS buffer
(PBS/2%FBS) and the binding was analyzed on BD FACScanto I
instrument.
Cell characterization
Macrophage phenotyping by RT PCR. RNA from
0.6610
6 macrophages was isolated using Trizol as
recommended by the manufacturer (Invitrogen). cDNA was
amplified from 1 mg of RNA by random priming and real time
PCR was performed in triplicates using Applied Biosystem’s
primers for IL-12-p35, IL-10, TNF-a, IL-6, b-actin. Data
acquisition and analysis was performed according Applied
Biosystem’s instructions.
Flow cytometry analysis. Prior to staining, non specific
binding sites on macrophages were blocked by incubation with
mouse IgG or CD16/32 Ab (5 mg/ml) for 10 min at 4uC. Abs
were added at manufacturer recommended concentrations and
incubated for 30–45 min at 4uC in the dark. 7-AAD was added to
distinguish dead cells 15 min before data acquisition. Detection of
mesothelin on macrophage surface was performed in a buffer
containing calcium (10 mM Hepes, 140 mM NaCl, 2.5 mM
CaCl2, 1%FBS, 0.1% NaN3) to maintain the lectin binding
properties of CD206 [101] for 30 min at 4uC in the dark.
Sodium azide was used to prevent passive endocytosis.
Intracellular staining was performed after surface labeling;
cells were incubated in permeabilization/fixation buffer
(eBiosciences) and incubated with antibodies for intracellular
staining as recommended by the manufacturer. Data were
obtained with BD FACScanto I instrument.
Cytokine Bead Array. Cytokine quantification was
performed using the multiplex kit for human IL-12-p70, IL-10,
IL-6, IFN-c, TNF-aand monoplex kit for human TGF-b from BD
Biosciences. Assays were performed using manufacturer’s
instructions.
Double determinant ELISA assays for detection of soluble
mesothelin and of GPI-anchor mesothelin
Detection of soluble mesothelin was performed using the
Human Mesothelin DuoSet kit (R&D Systems), as recommended
by the manufacturer. Ascites supernatants were diluted 1/100 and
1/1000 and cell line conditioned media was used undiluted or 1/
10 diluted in diluent (PBS/1% BSA). Detection of GPI-anchor
mesothelin was performed using anti-mesothelin K1 mAb at 5 ug/
ml as capture reagent and biotinylated-Endotoxin A at 2 ug/ml as
detection reagent, followed by SA-polyHRP and TMB (KPL).
Ascites supernatants were used undiluted or 1/100 diluted in
diluent (PBS/1% BSA); cell line conditioned media were used
undiluted. Plates were read using an ELISA plate reader (Biotek)
at 450 nm.
Biotinylated-Alpha Toxin
The plasmid pBRS10 encoding native alpha toxin [74]
expressing a histidine-tag was transformed BL21(DE3) pLysS E.
coli. Bacteria were grown in 2XYT media at 37uC overnight. The
culture was diluted 20 fold, at 1.0 OD protein expression was
induced for 4 hours at room temperature using 0.2 mM IPTG.
Bacterial pellets were resuspended in 0.5X PBS with protease
inhibitors and lysed using a French Press. Alpha toxin was purified
from the supernatant using Talon cobalt resin (Clontech). Bound
toxin was eluted using step immidazole gradients in 25 mM MES
pH 6.5 buffer supplemented with 150 mM NaCl. Alpha toxin
fractions were pooled and dialyzed to remove immidazole prior to
SP cation-exchange chromatography. Alpha toxin fractions were
concentrated and buffer exchanged into 25 mM MES pH 6.5,
150 mM NaCl before storage at -80uC. Purified toxin was
dialyzed into 1X PBS pH 9.0 prior to biotin labeling using
Sulfo-NHS-LC-Biotin (Pierce) as recommended by the manufac-
turer followed by buffer exchange using a 10,000 MWCO
membrane.
Lipidomic analysis
Isolation of lipid raft fraction from OvCar3 whole membrane
was performed after cell lysis by three rounds of freeze-thawing in
presence of 20 mM Tris-HCl pH 7.5, 0.5 mM EDTA and
protease inhibitor cocktail. Cell homogenates were passed through
a 26-gauge needle 10 times, sonicated (3 pulses of 15 sec., on ice),
and separated by sucrose gradient (40-5%). After ultracentrifuga-
tion at 200,000 g for 14 hrs, lipid rafts appeared as two discrete
bands that were separated by electrophoresis and probed by
western blot with anti-mesothelin mAb K1 at dilution 1/1000
(data not shown).
Mesothelin was immunoprecipitated from 50 ml of OVCAR3
conditioned medium (CM). CM was harvested, concentrated 10
times (Millipore centrifuge concentrator, 10 K cut-off), and
incubated overnight with 5 mg/ml of anti-mesothelin biobody P4
[63] at 4uC. Mesothelin/P4 complexes were retrieved with 150 ml
of pre-washed Dynal Myone streptavidin magnetic beads
(Myltenyi), for 2 hrs at 4uC. Beads bound to mesothelin/P4
complexes were magnetically separated, validated by western blot
for the presence of bound mesothelin using anti-mesothelin mAbs
and submitted to lipid analysis by tandem mass spectrometry.
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Lipid molecular profiles were obtained for each separated class
(phosphatidylcholine (PC), sphingomyelin (SM), cholesterol acetyl
ester) using the triple quadrupole API3000 (AB Sciex, Toronto,
Canada). The parent molecular species of lipids varies as a
function of their fatty acid composition. The scan of parent lipids is
obtained as the precursor of a class specific product ion cleaved
after low energy collision induced dissociation (CID) such as
phosphorylcholine (+184) for phosphatidylcholine and sphingo-
myelin or dehydrated cholesterol anion (+364) for sterides
[45,102].
Western Blot analysis
Immunoprecipitated mesothelin from tumor conditioned media
and tumor cell lysates were loaded on pre-cast gradient (4-15%)
gels and allowed to run for 60 min, 120V. Protein were transferred
by semidry transfer on Immobilon P transfer membrane for
30 min. Membranes were blocked overnight with 5% milk/PBST
and blotted for Mesothelin, TSG101 and Alix, using goat anti-
human mesothelin, rabbit anti-human TSG101, and mouse anti-
human Alix, respectively, at 1 mg/ml. Membranes were washed 3
times with PBST and blotted with secondary antibodies to mouse,
goat and rabbit at a dilution of 1/5,000. b-actin was detected using
HRP-labeled anti-human b-actin at a dilution of 1/30,000.
Membranes were incubated with ECL Plus (GE Healthcare) for
5 min and exposed to films for 15–30sec.
Supporting Information
Figure S1 Phenotype characterization of CD206
low and
CD206
high macrophages. A-B. Reverse microscopy analysis
(A) and flow cytometry analysis (B) for extracellular expression of
CD68, CD163 and CD206 (as indicated) of CD206
low (upper
panels) and CD206
high macrophages (lower panels). C–D.
mRNA levels and intracellular expressions of IL-12 (upper
panels) and IL-10 (lower panels) at different time points after
cytokine stimulation, as indicated.
(TIF)
Figure S2 Validation of anti-CRD4 MR scFvs. A. Capture
ELISA. Serial dilutions (10-0.01 mg/ml) of plastic immobilized
anti-CRD4 MR scFvs #G11 (open squares), #B2 (open
diamonds) and #H11 (open triangles) were incubated with
0.2 mg/ml of biotinylated recombinant CRD4-MR protein (lines)
or 2 mg/ml of irrelevant control antigen (black square). Binding
was detected with SA-HRP. Colorimetric signal were developed
with TMB substrate solution, quenched with sulfuric acid and read
at 450 nm on a Biotek ELISA reader. B. Flow cytometry analysis.
Anti-CRD4-MR scFvs #B2, #G11 and #H11 were premixed
with anti-V5 mAb and incubated with (upper panels) CD206
null
monocytes, (middle panels) CD206
low macrophages, and
(lower panels) CD206
high macrophages. As positive controls,
macrophages were labeled with anti-CD206 mAb (left panels).
Solid lines, anti-mannose receptor antibodies or recombinant
antibodies (scFv); grey areas: isotype control IgG1 mAb.
(TIF)
Figure S3 Characterization of monocytes and CD206
low
macrophages after co-culture with OVCAR3 ovarian
cancer cell line. A. Flow cytometry analysis of the percentage of
CD206
null monocytes (black bars) and of CD206
low macro-
phages (white bars) that expressed CD206, before or after 72hr
co-culture, as indicated. B–C. Transcriptional analysis of (B)
CD206
null monocytes and (C) CD206
low macrophages for TGF-b,
IL-10, IFN-c, TNF-a, IL-12, IL-6 after 72hr-incubation in
medium or co-culture, as indicated.
(TIF)
Figure S4 Effects of mannan and anti-CRD4 MR scFvs
on CD206
high macrophage phenotype during co-culture
with ovarian cancer cell lines. A. Flow cytometry analysis of
CD206 (black bars) and SR-A (white bars) expressions on
CD206
high macrophages incubated in medium or co-cultured with
OVCAR3 cells in medium or in the presence of mannan, or anti-
CRD4 MR scFv #B2, #G11 or #H11. As controls, macrophages
were stained with isotype control antibodies. B-I. CD206
high
macrophages were incubated in medium (1–2) or co-cultured with
OVCAR3 (3–4) or OVCAR5 (5–6) cells for 72hrs. 5 mg/ml of
anti-CRD4 MR scFv #G11 was added in the conditions 2, 4 and
6. Real-Time PCR (B–E) and cytokine bead arrays (F–I) were
performed to measure IL-10 (B,F), IL-12 (C,G), and TNF-a
(D,H).
(TIF)
Table S1 Germline immunoglobulin gene usage of the
predicted amino-acid sequence of the anti-CRD4 MR
scFvs B2, G11 and H11. The homology of light (L) and heavy
(H) chain variable regions to germline immunoglobulin genes is
displayed for each anti-CRD4 MR scFv.
(TIF)
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